Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Peanut allergy immunotherapy - DBV Technologies

Next Previous
Drug Profile

Peanut allergy immunotherapy - DBV Technologies

Alternative Names: Current Viaskin peanut patch; cVP; DBV 712; EPIT®; Modified Viaskin peanut patch; mVP; Viaskin Peanut; ViaskinTM Peanut

Latest Information Update: 14 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DBV Technologies
  • Class Allergens; Antiallergics; Food allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Peanut hypersensitivity

Most Recent Events

  • 09 Nov 2023 Interim efficacy and safety data from the phase III EPOPEX trial in Peanut hypersensitivity released by DBV Technologies
  • 31 Oct 2023 DBV Technologies plans the phase III COMFORT Children trial for Peanut hypersensitivity (In children) (Cutaneous, Patch)
  • 31 Oct 2023 DBV Technologies plans the phase III COMFORT Toddlers trial for Peanut hypersensitivity (In infants, In children) in Q1 2023 (Cutaneous, Patch)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top